GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Gross-Profit-to-Asset %

CTOR (Citius Oncology) Gross-Profit-to-Asset % : 0.00% (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Citius Oncology's annualized Gross Profit for the quarter that ended in Sep. 2024 was $0.00 Mil. Citius Oncology's average Total Assets over the quarter that ended in Sep. 2024 was $66.05 Mil. Therefore, Citius Oncology's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 0.00%.

Citius Oncology Gross-Profit-to-Asset % Historical Data

The historical data trend for Citius Oncology's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Gross-Profit-to-Asset % Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
Gross-Profit-to-Asset %
- - -

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
Gross-Profit-to-Asset % - - -

Competitive Comparison of Citius Oncology's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Oncology's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Citius Oncology's Gross-Profit-to-Asset % falls into.


Citius Oncology Gross-Profit-to-Asset % Calculation

Citius Oncology's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Sep. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Sep. 2024 )/( (Total Assets (A: Sep. 2023 )+Total Assets (A: Sep. 2024 ))/ count )
=0/( (47.735+84.369)/ 2 )
=0/66.052
=0.00 %

Citius Oncology's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Sep. 2024 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Sep. 2024 ))/ count )
=0/( (47.735+84.369)/ 2 )
=0/66.052
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is one times the annual (Sep. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Citius Oncology Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Gross-Profit-to-Asset %
Comparable Companies
INCR ASRT CPIX DERM RGC OPTN RMTI MRMD ETST SCYX ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ XTAE:TEVA NSE:DIVISLAB HKSE:03692
Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Website
https://www.citiusonc.com
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.